OptimizeRx (NASDAQ:OPRX) Insider Sells $18,751.88 in Stock

OptimizeRx Corp. (NASDAQ:OPRX) insider Edward Stelmakh sold 1,388 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $13.51, for a total value of $18,751.88. Following the completion of the transaction, the insider owned 126,830 shares in the company, valued at approximately $1,713,473.30. The trade was a 1.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

OptimizeRx Stock Performance

Shares of OPRX traded up $0.09 during mid-day trading on Monday, hitting $13.60. The stock had a trading volume of 63,936 shares, compared to its average volume of 358,041. OptimizeRx Corp. has a 52 week low of $3.99 and a 52 week high of $22.25. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.05 and a quick ratio of 3.05. The business has a fifty day moving average price of $16.56 and a 200-day moving average price of $15.98. The firm has a market cap of $253.42 million, a P/E ratio of 33.78 and a beta of 1.10.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.17. The company had revenue of $26.07 million during the quarter, compared to analyst estimates of $23.83 million. OptimizeRx had a return on equity of 6.37% and a net margin of 0.03%. On average, equities research analysts expect that OptimizeRx Corp. will post -0.33 EPS for the current year.

Institutional Trading of OptimizeRx

Institutional investors and hedge funds have recently made changes to their positions in the stock. Nisa Investment Advisors LLC raised its position in OptimizeRx by 600.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock valued at $29,000 after purchasing an additional 1,818 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of OptimizeRx during the 2nd quarter valued at about $44,000. BNP Paribas Financial Markets lifted its position in OptimizeRx by 119.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after buying an additional 2,215 shares during the last quarter. MetLife Investment Management LLC purchased a new stake in OptimizeRx in the first quarter worth approximately $99,000. Finally, USA Financial Formulas purchased a new stake in OptimizeRx in the third quarter worth approximately $131,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on OPRX. UBS Group set a $23.00 target price on OptimizeRx in a research report on Friday, October 10th. Weiss Ratings reissued a “sell (d+)” rating on shares of OptimizeRx in a report on Monday, December 15th. Citigroup reaffirmed an “outperform” rating on shares of OptimizeRx in a research note on Friday, October 10th. Wall Street Zen upgraded shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Finally, JMP Securities boosted their price target on shares of OptimizeRx from $20.00 to $23.00 and gave the company a “market outperform” rating in a research report on Friday, October 10th. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, OptimizeRx has an average rating of “Moderate Buy” and an average price target of $16.88.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.